{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-169713","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.803991+00:00","generated_at":"2026-06-01T00:59:19.766516+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.68,"calibrated_materiality_score":0.68,"confidence":"high","headline":"Lantheus acquires global rights to Life Molecular's GRPR-targeting radiotheranostic pair for $35M upfront","bullets":["Upfront payment $35M plus regulatory milestone payments and royalties.","Pair includes 177Lu-DOTA-RM2 (therapeutic) and 68Ga-DOTA-RM2 (diagnostic) targeting GRPR in prostate, breast, and other cancers.","Lantheus plans Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer in 2025; 68Ga-DOTA-RM2 as companion diagnostic.","Strengthens Lantheus' prostate cancer portfolio and expands pipeline to include breast cancer.","Life Molecular will complete ongoing Phase 1/2a dose escalation study in collaboration with Lantheus."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-169713","json":"https://secwatch.observer/filing/0001193125-24-169713.json","markdown":"https://secwatch.observer/filing/0001193125-24-169713.md","text":"https://secwatch.observer/filing/0001193125-24-169713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312524169713/0001193125-24-169713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312524169713/d651116d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:59:19.766516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}